The Difference is a Miracle!

The Miracle of Childbirth may not be new or different – but what if that miracle was recycled to become a revolutionary, all-natural, regenerative products for horses with wounds and leg injuries as a much better, faster, safer and less expensive alternative to all other competing regenerative therapies on the market?  What if horses receiving that product resumed activities in half the time* and were re-injured 5 times less* than with other treatments?

AniCell Biotech’s EquusCell Brand products are distinctly different! Our patented process of non-invasively capturing miracle-laden mesenchymal stem cells from the amniotic material during parturition and putting them back to work accelerating the regeneration of tissue and bone in injured horses sets us apart from the herd.

EquusCell is better due to the significant regenerative effects of amniotic material with natural anti-inflammatory, anti-microbial, and anti-adhesion properties.  Our products include fetal amniotic material such as collagens, proteins, carbohydrates, hyaluronic acid, laminin, fibronectin and other growth factors necessary for rebuilding extracellular matrix tissues.

“The EquusCell product line can be used for suspensory lesions, superficial digital flexor tendon ruptures, stifle and hock inflammation and other orthopedic injuries.  It can even be used as a preventative product in young horses to aid in development during training.” – Dr. Moises Fimbres Barcelo, DVM Ph.D.

It is truly the miracle of childbirth that makes EquusCell’s products faster! Amnion is immune privileged; it lacks cellular blood markers (type 2 MHC) that would typically cause rejection of this type of transplant. This allows us to address injuries the same day in like species animals.

EquusCell is safer! It is non-invasive — it does not require painful harvesting of bone marrow or fat or the risk of sedation or anesthetics.

EquusCell’s products are also less expensive! It does not require lab work, shipping of harvesting kits for fat or bone marrow samples or the resources to culture them and there is no need for multiple applications.

Brandon Ames, CEO of AniCell Biotech said: “Quite simply, we are in the recycling business, collecting the miracles of nature’s blessings that would otherwise end up on the ground.”

*Cytotherapy, 2013; 0:1-10; International Society for Cellular Therapy. Investigating the efficacy of amnion-derived compared with bone marrow-derived mesenchymal stromal cells in equine tendon and ligament injuries, ANNA LANGE-CONSIGLIO, STEFANO TASSAN, BRUNA CORRADETTI, AURORA MEUCCI, ROBERTA PEREGO, DAVIDE BIZZARO & FAUSTO CREMONES